Cardinal Health Inc.
Cardinal Health, Inc. (CAH)
Overview
Cardinal Health is a healthcare services and products company headquartered in Dublin, Ohio, operating in the healthcare distribution industry within the Healthcare sector. Founded in 1971 by Robert D. Walter as a food wholesaler called Cardinal Foods, the company pivoted into pharmaceutical distribution in 1979 through the acquisition of Bailey Drug Company, went public in 1983, and adopted the Cardinal Health name in 1994. It is one of the largest pharmaceutical and medical-product distributors in the United States, supplying more than 100,000 pharmacies, hospitals, and healthcare facilities and serving over 75% of U.S. hospitals. The company is enormous by revenue but thin by margin — fiscal year 2026 revenue reached roughly $254 billion, generated by a workforce of about 58,000 employees, reflecting the low-margin, high-volume economics typical of pharmaceutical wholesaling.
What They Do & How They Make Money
Cardinal Health sits in the middle of the healthcare supply chain, buying pharmaceuticals and medical products in bulk from manufacturers and distributing them efficiently to pharmacies, hospitals, physician offices, surgery centers, and long-term care facilities. Because it is essentially a logistics and distribution intermediary, its profit comes not from big markups (margins are razor-thin, often around 1% operating margin) but from enormous transaction volume, negotiated purchasing discounts and rebates from drug manufacturers, generic drug sourcing economics, and fees for value-added services like inventory management, data analytics, and specialty pharmacy support. A meaningful and growing share of profit comes from higher-margin generic pharmaceuticals, where Cardinal Health can negotiate favorable sourcing terms and pass along a portion of the savings while keeping a spread. The company also manufactures and distributes its own branded medical products — gloves, surgical apparel, wound care items, and fluid management supplies — under brands and through its Global Medical Products and Distribution business, which carries somewhat higher margins than pure pharmaceutical distribution. Additionally, Cardinal Health operates one of the largest radiopharmacy networks in the country, compounding and delivering short-half-life nuclear medicine doses used in diagnostic imaging and, increasingly, targeted radiotherapy for cancer treatment — a specialized, higher-margin niche business.
Business Segments
Cardinal Health reports primarily through segments reflecting its dual identity as a drug wholesaler and a medical products company:
- Pharmaceutical and Specialty Solutions (formerly Pharmaceutical Distribution): By far the largest segment, representing roughly 92% of total revenue (approximately $235 billion in FY2026). This segment distributes brand-name and generic pharmaceuticals to retail and hospital pharmacies, and includes Cardinal Health's specialty pharmaceutical distribution business, which handles complex, high-cost specialty drugs (oncology, biologics) requiring specialized handling and provider support services.
- Global Medical Products and Distribution (GMPD): Roughly 5% of revenue (about $12.7 billion), covering manufacturing and distribution of medical, surgical, and laboratory products — exam gloves, surgical apparel and drapes, wound care, and fluid management — sold to hospitals, surgery centers, and other providers, both under Cardinal Health's own brands and third-party brands.
- Other (including at-Home Solutions and Nuclear/Precision Health Solutions): About 3% of revenue (roughly $6.8 billion), encompassing the radiopharmacy network (Nuclear & Precision Health Solutions), home healthcare/medical equipment distribution (at-Home Solutions), and other emerging businesses.
Despite generating the vast majority of revenue, the Pharmaceutical and Specialty Solutions segment's razor-thin margins mean that GMPD and the specialty/nuclear businesses contribute disproportionately to segment profit relative to their revenue share.
Competitors
- Pharmaceutical distribution: McKesson Corporation and Cencora (formerly AmerisourceBergen) are Cardinal Health's two primary direct competitors; together, the three companies form an oligopoly controlling the large majority of U.S. pharmaceutical wholesale distribution.
- Medical products distribution/manufacturing: Owens & Minor, Medline Industries (private), and Henry Schein compete in medical-surgical products distribution.
- Specialty pharmacy/radiopharmacy: Curium Pharma and smaller regional nuclear pharmacy networks compete in radiopharmaceutical distribution; specialty distribution also competes indirectly with vertically integrated pharmacy benefit managers and specialty pharmacies operated by CVS Health and UnitedHealth Group's Optum.
- Adjacent/vertical integration threats: Large retail pharmacy chains and PBM-owned distribution arms (CVS Caremark, Cigna's Express Scripts/Accredo, UnitedHealth's OptumRx) increasingly integrate distribution functions in-house, representing both customers and potential competitive threats.
Competitive Position
Cardinal Health's moat rests on scale, an entrenched logistics network, and deep, long-standing relationships with both drug manufacturers and healthcare providers — advantages that are extremely difficult for a new entrant to replicate given the regulatory complexity (DEA licensing, controlled substance tracking, cold-chain and radioactive-material handling) and capital intensity of pharmaceutical distribution. Along with McKesson and Cencora, Cardinal Health benefits from an effective oligopoly structure in U.S. drug wholesaling, and its national footprint reaching the vast majority of U.S. hospitals gives it negotiating leverage with manufacturers. Its radiopharmacy network and specialty distribution business represent higher-margin growth areas tied to the secular rise of biologics, oncology drugs, and nuclear medicine, positioning Cardinal Health to benefit from the increasing complexity of the drug supply chain. That said, the company faces persistent structural risks: extraordinarily thin margins leave profitability vulnerable to small swings in generic drug pricing (deflation in generics has periodically pressured earnings), customer concentration among large retail pharmacy chains and PBMs gives buyers significant pricing power, and the company has faced substantial legal and reputational exposure from its role in the U.S. opioid crisis, resulting in multibillion-dollar settlement obligations paid out over many years. Additionally, ongoing vertical integration in healthcare — as insurers, PBMs, and large retailers bring distribution functions in-house — poses a long-term disintermediation risk to the traditional wholesaler role that Cardinal Health has occupied for decades.